# Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)

> **NCT05085574** · PHASE2 · WITHDRAWN · sponsor: **Leidos Life Sciences**

## Conditions studied

- 2019 Novel Coronavirus Disease
- 2019 Novel Coronavirus Infection
- 2019-nCoV Disease
- 2019-nCoV Infection
- COVID-19 Pandemic
- COVID-19 Virus Disease
- COVID-19 Virus Infection
- Covid19
- Coronavirus Disease 2019
- SARS-CoV-2 Infection
- SARS-CoV-2 Acute Respiratory Disease
- COVID-19

## Interventions

- **DRUG:** Famotidine
- **DRUG:** Celecoxib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05085574
- **Lead sponsor:** Leidos Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-02-07
- **Primary completion:** 2023-02-07
- **Final completion:** 2023-02-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** COVID environment, lack of site confidence to enroll subjects, sites not suited to study procedures, decline of potential inpatient subjects at site
- **Last updated:** 2023-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05085574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05085574, "Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05085574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*